全文获取类型
收费全文 | 5732篇 |
免费 | 267篇 |
国内免费 | 54篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 86篇 |
妇产科学 | 80篇 |
基础医学 | 640篇 |
口腔科学 | 87篇 |
临床医学 | 374篇 |
内科学 | 1646篇 |
皮肤病学 | 47篇 |
神经病学 | 409篇 |
特种医学 | 209篇 |
外科学 | 1085篇 |
综合类 | 17篇 |
一般理论 | 2篇 |
预防医学 | 124篇 |
眼科学 | 66篇 |
药学 | 544篇 |
中国医学 | 13篇 |
肿瘤学 | 569篇 |
出版年
2023年 | 28篇 |
2022年 | 58篇 |
2021年 | 81篇 |
2020年 | 48篇 |
2019年 | 79篇 |
2018年 | 82篇 |
2017年 | 61篇 |
2016年 | 105篇 |
2015年 | 102篇 |
2014年 | 149篇 |
2013年 | 148篇 |
2012年 | 240篇 |
2011年 | 278篇 |
2010年 | 152篇 |
2009年 | 146篇 |
2008年 | 274篇 |
2007年 | 268篇 |
2006年 | 255篇 |
2005年 | 259篇 |
2004年 | 240篇 |
2003年 | 258篇 |
2002年 | 248篇 |
2001年 | 220篇 |
2000年 | 223篇 |
1999年 | 214篇 |
1998年 | 62篇 |
1997年 | 40篇 |
1996年 | 38篇 |
1995年 | 39篇 |
1994年 | 41篇 |
1993年 | 22篇 |
1992年 | 143篇 |
1991年 | 150篇 |
1990年 | 156篇 |
1989年 | 179篇 |
1988年 | 127篇 |
1987年 | 136篇 |
1986年 | 111篇 |
1985年 | 116篇 |
1984年 | 69篇 |
1983年 | 48篇 |
1982年 | 23篇 |
1979年 | 39篇 |
1978年 | 29篇 |
1975年 | 19篇 |
1974年 | 24篇 |
1973年 | 20篇 |
1972年 | 28篇 |
1971年 | 25篇 |
1969年 | 20篇 |
排序方式: 共有6053条查询结果,搜索用时 15 毫秒
981.
T. Fujimoto T. Andoh T. Sudo I. Fujita M. Imabori H. Moritake T. Sugimoto Y. Sakuma T. Takeuchi H. Sonobe Alan L. Epstein T. Akisue M. Kirihata M. Kurosaka Y. Fukumori H. Ichikawa 《Applied radiation and isotopes》2011,69(12):1713-1716
Clear cell sarcoma (CCS), a rare malignant tumor with a predilection for young adults, is of poor prognosis. Recently however, boron neutron capture therapy (BNCT) with the use of p-borono‐L‐phenylalanine (BPA) for malignant melanoma has provided good results. CCS also produces melanin; therefore, the uptake of BPA is the key to the application of BNCT to CCS. We describe, for the first time, the high accumulation of boron in CCS and the CCS tumor-bearing animal model generated for BNCT studies. 相似文献
982.
Branched‐chain amino acid‐enriched nutrient increases blood platelet count in patients after endoscopic injection sclerotherapy
下载免费PDF全文
![点击此处可从《Hepatology research》网站下载免费的PDF全文](/ch/ext_images/free.gif)
983.
Computer‐aided diagnosis for estimating the malignancy grade of hepatocellular carcinoma using contrast‐enhanced ultrasound: an ROC observer study
下载免费PDF全文
![点击此处可从《Liver international》网站下载免费的PDF全文](/ch/ext_images/free.gif)
984.
985.
Tomoe Koizumi PhD Yodo Sugishita MD PhD Yuki Suzuki-Takahashi MD PhD Kazuko Nara MA Tomoko Miyagawa MA Misako Nakajima MA Kouhei Sugimoto MD PhD Manabu Futamura MD PhD Tatsuro Furui MD PhD Yasushi Takai MD PhD Hiroshi Matsumoto MD PhD Hideko Yamauchi MD Shinji Ohno MD PhD Akemi Kataoka MD PhD Kiyotaka Kawai MD PhD Eisuke Fukuma MD PhD Hiroko Nogi MD PhD Koichiro Tsugawa MD PhD Nao Suzuki MD PhD 《Cancer》2023,129(16):2568-2580
986.
987.
988.
Tadao Yoshida Satofumi Sugimoto Masaaki Teranishi Hironao Otake Masahiro Yamazaki Shinji Naganawa Tsutomu Nakashima Michihiko Sone 《Auris, nasus, larynx》2018,45(1):33-38
Objective
To examine endolymphatic hydrops (EH) using magnetic resonance imaging (MRI) in patients with definite Ménière’s disease (MD) and those with nonotological diseases.Methods
We studied 32 patients with unilateral MD, 10 patients with bilateral MD and 21 patients with control ears who had other benign diseases not associated with hearing or vestibular dysfunction. The mean age of the subjects was 54.0 years (range 27–74) in the MD group and 56.1 years (range 24–79) in the control group. Using MRI, the degree of EH was classified as none, mild and significant in the cochlea and vestibule separately. The ratio of the area of endolymphatic space to the vestibular fluid space was calculated for the vestibule. The duration of MD was defined as the months between the first attack of MD and the MRI study.Results
EH was present in the cochlea of 45/52 affected ears of patients with MD (87%) and in 16/42 control ears (38%). Significant cochlear hydrops was present in 37/52 affected ears (71%) and in 4/42 control ears (10%). EH in the vestibule was present in 49/52 affected ears (94%) and in 3/42 control ears (7%). Significant vestibular hydrops was present in 40/52 affected ears (77%) and in none of the 42 control ears. There was no relationship between the degree of EH and its duration. Using a cut off value for the relative size of EH in the vestibule of 41.9%, the test had a sensitivity of 88.5% and a specificity of 100% to diagnose definite MD.Conclusion
Cochlear EH was occasionally observed in control ears on MRI, as in normal temporal bone specimens. The presence or absence and degree of vestibular EH were significantly different between ears with MD and control ears. EH in the vestibule might be a specific predictor of definite MD. 相似文献989.
990.
Noriyoshi Iriyama Kei-Ji Sugimoto Eriko Sato Tomoiku Takaku Michihide Tokuhira Tomonori Nakazato Maho Ishikawa Hiroyuki Fujita Isao Fujioka Yuta Kimura Norio Asou Masahiro Kizaki Norio Komatsu Yoshihiro Hatta Tatsuya Kawaguchi 《Medical oncology (Northwood, London, England)》2018,35(11):142
Treatment with a tyrosine kinase inhibitor (TKI) is the standard of care for patients with chronic myeloid leukemia (CML). The new-generation TKIs, nilotinib and dasatinib, are found to have deeper and faster treatment response rates compared to imatinib in the first-line setting. However, a direct comparison between nilotinib and dasatinib has never been reported previously. Our study aims to compare the outcomes and molecular responses achieved following the first-line use of these two agents in patients with CML-CP. The database of the CML Cooperative Study Group was reviewed and patients with CML in the chronic phase (CP) who were given nilotinib or dasatinib as first-line therapy were identified. Out of 361 patients with CML-CP enrolled in our database, 58 and 63 had been treated with conventional doses of nilotinib (300 mg twice daily) and dasatinib (100 mg once daily), respectively, as first-line therapy. The patient demographics did not show significant differences between the groups. The event-free survival rates did not differ between these two groups. The major molecular response (MMR) and the deep molecular response (DMR) rates by 6, 12, 18, and 24 months did not differ between groups. Among the three scoring systems, only the Hasford score could predict the achievement of DMR, and all of them failed to predict the achievement of MMR in the entire cohort. Our data suggest that both nilotinib and dasatinib have comparable efficacies and promising outcomes. 相似文献